IndustryCompany release

iRhythm raises 2026 revenue guidance after VitalConnect deal and Q3 revenue rise to $221.6M

🇺🇸 iRhythm Holdings, Inc. (IRTC) · Thu 05 Nov 2026

The Zio maker reported third-quarter revenue of $221.6 million, completed its VitalConnect acquisition and filed FDA 510(k) applications for paediatric use of Zio Monitor.

iRhythm Holdings reported third-quarter 2026 results on 5 November, with revenue of $221.6 million, a GAAP net loss of $29.9 million and adjusted EBITDA of $51.2 million. The company raised its full-year revenue guidance to $890-895 million.

The company completed its acquisition of VitalConnect on 5 October. The deal adds an FDA-cleared mobile cardiac telemetry device to iRhythm's Zio cardiac monitoring portfolio.

iRhythm has also submitted FDA 510(k) applications for paediatric use of Zio Monitor. A 510(k) is the premarket notification route under which a manufacturer shows that a device is substantially equivalent to a legally marketed device. The summary does not give the submission dates or the specific age groups covered.

On 3 November the company closed a new $300 million senior secured revolving credit facility. No further terms of the facility are available in the material provided.

What it means for your team

  • The VitalConnect acquisition brings a second FDA-cleared cardiac monitoring device into the Zio portfolio, so quality and regulatory teams should expect integration work across the combined product range.
  • The paediatric 510(k) submissions are pending; any clearance would extend the indicated population for Zio Monitor, and decisions should be tracked on the FDA database.
  • Raised guidance and a new credit facility give context on the company's financial position for market-access and partnership planning.

Company's press release (SEC filing): iRhythm Holdings, Inc. ↗

Article written by VigiEye from the official source (iRhythm Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →